|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.710 USD | -2.11% |
|
-4.13% | +10.09% |
| 07-14 | Ironwood Pharmaceuticals, Inc. Announces Management Changes | CI |
| 05-27 | Ironwood Says US FDA Approves Linzess Use in Children Aged Two Years and Older With Functional Constipation | MT |
Company Valuation: Ironwood Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,908 | 1,901 | 1,786 | 708.9 | 548.2 | 610.7 | - | - |
| Change | - | -0.4% | -6.02% | -60.31% | -22.67% | 11.4% | - | - |
| Enterprise Value (EV) | 1,742 | 1,641 | 1,786 | 708.9 | 548.2 | 610.7 | 610.7 | 610.7 |
| Change | - | -5.83% | 8.87% | -60.31% | -22.67% | 11.4% | 0% | 0% |
| P/E | 3.63x | 12.9x | -1.77x | 443x | 22.5x | 3.13x | 3x | 2.63x |
| PBR | 3.12x | 3.54x | - | - | - | - | - | - |
| PEG | - | -0.2x | 0x | -4x | 0x | 0x | 0.71x | 0.2x |
| Capitalization / Revenue | 4.61x | 4.63x | 4.03x | 2.02x | 1.85x | 1.33x | 1.28x | 1.25x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 1.33x | 1.28x | 1.25x |
| EV / EBITDA | 0x | 0x | -0x | 0x | 0x | 1.87x | 1.82x | 1.79x |
| EV / EBIT | 0x | 0x | -0x | 0x | 0x | 2.05x | 2.09x | 1.99x |
| EV / FCF | 0x | 0x | 0x | 0x | 0x | 2.57x | 2.26x | 2.21x |
| FCF Yield | 13.7% | 14.4% | 10.3% | 14.6% | 23.2% | 39% | 44.2% | 45.3% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 3.21 | 0.96 | -6.45 | 0.01 | 0.15 | 1.185 | 1.235 | 1.41 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 413.8 | 410.6 | 442.7 | 351.4 | 296.2 | 460.1 | 478.4 | 488.9 |
| EBITDA 1 | 233.7 | 251.8 | -884.8 | 100.6 | 138.1 | 326.1 | 334.8 | 341.9 |
| EBIT 1 | 232.2 | 250.3 | -945.4 | 94.85 | 98.5 | 297.2 | 292.8 | 307.3 |
| Net income 1 | 528.4 | 175.1 | -1,002 | 1.813 | 24.02 | 181.6 | 209.9 | 232 |
| Net Debt | -165.9 | -260 | - | - | - | - | - | - |
| Reference price 2 | 11.660 | 12.390 | 11.440 | 4.430 | 3.370 | 3.710 | 3.710 | 3.710 |
| Nbr of stocks (in thousands) | 163,650 | 153,395 | 156,129 | 160,028 | 162,679 | 164,613 | - | - |
| Announcement Date | 2/17/22 | 2/16/23 | 2/15/24 | 2/27/25 | 2/25/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 3.2x | - | - | - | 624M | |
| 66.43x | 5.38x | 20.22x | 2.6% | 322B | |
| 23.56x | 3.23x | 11.52x | 1.68% | 68.84B | |
| 12.12x | 6.17x | 9.58x | - | 9.59B | |
| 16.79x | 2.13x | 7.29x | 2.65% | 8.29B | |
| 21.26x | 6.02x | 17.02x | -.--% | 4.23B | |
| 32.49x | 6.17x | 17.63x | - | 3.77B | |
| 39.21x | 2.24x | 28.16x | 0.78% | 3.61B | |
| 106.04x | - | - | -.--% | 2.74B | |
| Average | 35.68x | 4.48x | 15.92x | 1.29% | 47.11B | |
| Weighted average by Cap. | 56.45x | 4.97x | 18.31x | 2.39% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- IRWD Stock
- Valuation Ironwood Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
